1. Plasma Interleukin-6 and Fatigue in Terminally Ill Cancer Patients
Masatoshi Inagaki, MD, PhD, Masako Isono, MD, Toru Okuyama, MD, PhD, Yuriko Sugawara, MD, PhD, Tatsuo Akechi, MD, PhD, Nobuya Akizuki, MD, PhD, Maiko Fujimori, PhD, Motoko Mizuno, PhD, Yasuo Shima, MD, Hiroya Kinoshita, MD, Yosuke Uchitomi, MD, PhD 
Journal of Pain and Symptom Management 
Volume 35, Issue 2, Pages (February 2008)
DOI: /j.jpainsymman
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Figure 1
Plasma IL-6 concentrations of terminally ill cancer patients with and without clinical fatigue. Horizontal bars indicate the mean values of IL-6 in cancer patients with and without clinical fatigue. A superimposed scattered image indicates logarithmic-transformed IL-6 in cancer patients with and without clinical fatigue.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Figure 2
Plasma IL-6 concentrations and each of the subscale scores of the CFS. Solid and open circles indicate the values of patients with and without clinical fatigue, respectively. Superimposed scatter plots display IL-6 levels on logarithmic scales. Lines in the superimposed graphs indicate regression lines between logarithmically transformed IL-6 levels and each of the subscale scores.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions